Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 10/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14966820 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTLMNAMAPK14KLKB1 | |
| SCHEMBL14967422 | 0.85 | MAPK14 (0.56) | SMN1; SMN2LMNAMAPK14KLKB1 | |
| SCHEMBL14966826 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTLMNAKLKB1NR1H4 | |
| SCHEMBL14967045 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTLMNAKLKB1NR1H4 | |
| SCHEMBL14967364 | 0.82 | KDM4E (0.41) | SMN1; SMN2MAPTLMNAKLKB1 | |
| SCHEMBL14966641 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTKLKB1 | |
| SCHEMBL14967484 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTKLKB1 | |
| SCHEMBL14967162 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPTKLKB1 | |
| SCHEMBL14967281 | 0.82 | KDM4E (0.41) | SMN1; SMN2MAPTLMNAKLKB1 | |
| SCHEMBL14967151 | 0.82 | KDM4E (0.41) | SMN1; SMN2MAPTLMNAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051269-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | claimed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150315148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9051269-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051269-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140315949-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315949-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2780013-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2635588-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075084-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075084-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | SMN1; SMN2 3191/4885MAPT 3877/4885LMNA 3603/4885 |
| US-20140315949-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | SMN1; SMN2 3191/4885MAPT 3877/4885LMNA 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.